Literature DB >> 10672864

Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model.

K Miyata1, H Shimokawa, T Higo, T Yamawaki, N Katsumata, T Kandabashi, E Tanaka, Y Takamura, K Yogo, K Egashira, A Takeshita.   

Abstract

Serotonin is one of the most important vasoactive substances and has been implicated in the pathogenesis of coronary artery spasm and of acute coronary syndrome. We have recently demonstrated that local and long-term treatment with interleukin-1beta(IL-1beta) causes coronary arteriosclerotic changes and hyperconstrictive responses to serotonin in pigs in vivo. However, it remains to be examined which serotonergic (5-HT) receptor subtype mediates coronary spasm and whether alterations in serotonergic receptors are involved in the abnormality. In this study, we examined the inhibitory effect of sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, on the serotonin-induced coronary spasm as well as the possible alterations of serotonergic receptors in our porcine model. A segment of the porcine coronary artery was carefully dissected and aseptically wrapped with cotton mesh absorbing IL-1beta-bound microbeads from the adventitia. Two weeks after the procedure, angiographic study was performed, followed by binding assay for 5-HT1B and 5-HT2A serotonergic receptors and reverse transcription-polymerase chain reaction (RT-PCR) analysis for mRNA of those receptors. Angiographic study showed coronary vasospastic responses to serotonin at the IL-1beta-treated site. Sarpogrelate dose-dependently inhibited the serotonin-induced coronary spasm, but it did not affect the prostaglandin F2alpha-induced vasoconstriction. Radiolabeled receptor-binding assay showed that receptor affinity or receptor number of the 5-HT1B, or 5-HT2A receptors did not differ significantly between the spastic and the control sites. Furthermore, RT-PCR analysis showed that the expression of neither 5-HT2A nor 5-HT1B receptor mRNA was significantly altered at the spastic site. These results indicate that serotonin-induced coronary spasm is mediated primarily by 5-HT2A receptor in our porcine model, although the 5-HT2A receptor was not up-regulated, suggesting that alteration in the signal-transduction pathway for vascular smooth muscle contraction beyond the 5-HT2A receptor plays a primary role in the pathogenesis of coronary spasm in our porcine model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672864     DOI: 10.1097/00005344-200002000-00018

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Authors:  Matthew W Johnson; R Andrew Sewell; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

2.  The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes.

Authors:  Jeff C Huffman; Christopher M Celano; James L Januzzi
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 3.  Anxiety Disorders and Cardiovascular Disease.

Authors:  Christopher M Celano; Daniel J Daunis; Hermioni N Lokko; Kirsti A Campbell; Jeff C Huffman
Journal:  Curr Psychiatry Rep       Date:  2016-11       Impact factor: 5.285

4.  Sarpogrelate inhibits the expression of ICAM-1 and monocyte-endothelial adhesion induced by high glucose in human endothelial cells.

Authors:  Ying Su; Nan Mao; Min Li; Xia Dong; Fan-Zhen Lin; Ying Xu; Yan-Bo Li
Journal:  Mol Cell Biochem       Date:  2012-10-31       Impact factor: 3.396

5.  Depression and cardiac disease: epidemiology, mechanisms, and diagnosis.

Authors:  Jeff C Huffman; Christopher M Celano; Scott R Beach; Shweta R Motiwala; James L Januzzi
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-04-07

6.  The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.

Authors:  Kyungil Park; Woo-Young Chung; Jae-Bin Seo; Sang-Hyun Kim; Joo-Hee Zo; Myung-A Kim; Young-Bae Park
Journal:  Trials       Date:  2010-12-20       Impact factor: 2.279

7.  Angiotensin II, as well as 5-hydroxytriptamine, is a potent vasospasm inducer of saphenous vein graft for coronary artery bypass grafting in patients with diabetes mellitus.

Authors:  Atsuko Yokota; Shuji Gamoh; Naoko Tanaka-Totoribe; Tatsuo Shiba; Masachika Kuwabara; Eisaku Nakamura; Takahiro Hayase; Hiroaki Hisa; Kunihide Nakamura; Ryuichi Yamamoto
Journal:  Biochem Biophys Rep       Date:  2016-03-17

8.  Effect of sarpogrelate and high-dose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study.

Authors:  So Ree Kim; Ki Hong Choi; Young Bin Song; Joo Myung Lee; Taek Kyu Park; Jeong Hoon Yang; Joo-Yong Hahn; Jin-Ho Choi; Seung-Hyuk Choi; Hyeon-Cheol Gwon
Journal:  Clin Cardiol       Date:  2019-07-24       Impact factor: 2.882

9.  Upregulation of 5-hydroxytryptamine receptor signaling in coronary arteries after organ culture.

Authors:  Chun-Yu Deng; Hui Yang; Su-Juan Kuang; Fang Rao; Yu-Mei Xue; Zhi-Ling Zhou; Xiao-Ying Liu; Zhi-Xin Shan; Xiao-Hong Li; Qiu-Xiong Lin; Shu-Lin Wu; Xi-Yong Yu
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

10.  Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.

Authors:  Yahan Liu; Zhipeng Wang; Jing Li; Yiqian Ban; Guangmei Mao; Man Zhang; Mo Wang; Yan Liu; Beilei Zhao; Qiang Shen; Qingbo Xu; Nanping Wang
Journal:  J Am Heart Assoc       Date:  2018-01-30       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.